The story of Melinta Therapeutics' remarkable turnaround under new CEO Christine Miller is one of resilience and strategic progression. Facing significant commercial challenges, the company has navigated a Chapter 11 bankruptcy and emerged under private ownership. Miller's three-step plan focuses on strategic implications, exceptional capabilities, and expansion into new adjacencies. This strategic shift has not only revitalized the core business but also diversified its sources of growth. However, Miller remains concerned about the prevailing issues in the antibiotic-resistant infection market and advocates for a change in government policy to bolster the use of AMR drugs. Ultimately, Miller's plan has propelled Melinta onto a path of growth and resilience in the fight against antibiotic-resistant infections.